Compound Evidence File
#EC-2026-0941
LGD-4033 (Ligandrol)
Filed under Oral Tablets. The bureau holds 163 laboratory returns for this compound from 64 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
64 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| HomopeptideCASE #VI-2026-0760 | A | 6 | 10.0 | 9.9 | 10.0 | 21 May 2026 | 21 May 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 4 | 10.0 | 10.0 | 10.0 | 12 Mar 2026 | 23 Jun 2026 |
| PolyPeptide GroupCASE #VI-2026-0143 | A | 4 | 10.0 | 10.0 | 10.0 | 19 Feb 2026 | 11 Jul 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 3 | 10.0 | 9.9 | 10.0 | 7 Mar 2026 | 17 Jun 2026 |
| BachemCASE #VI-2026-0314 | A | 3 | 10.0 | 9.9 | 10.0 | 5 Apr 2026 | 7 May 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 3 | 10.0 | 9.9 | 10.0 | 15 Mar 2026 | 22 Jun 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 3 | 10.0 | 9.9 | 10.0 | 9 Feb 2026 | 26 Jun 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 3 | 10.0 | 9.9 | 10.0 | 11 May 2026 | 8 Jun 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 3 | 10.0 | 9.9 | 10.0 | 14 Apr 2026 | 26 May 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 3 | 10.0 | 9.9 | 10.0 | 6 Mar 2026 | 2 Jun 2026 |
| AsymchemCASE #VI-2026-0091 | A | 3 | 10.0 | 9.9 | 10.0 | 19 Apr 2026 | 2 Aug 2026 |
| Hybio PharmaceuticalCASE #VI-2026-0065 | A | 2 | 10.0 | 10.0 | 10.0 | 21 Jun 2026 | 3 Jul 2026 |
| Shanghai JinBei Chemical TechnologyCASE #VI-2026-0107 | X | 1 | 10.0 | 10.0 | 10.0 | 2 Apr 2025 | 2 Apr 2025 |
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 5 | 9.9 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 4 | 9.9 | 9.9 | 10.0 | 12 Feb 2026 | 6 Jul 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 4 | 9.9 | 9.9 | 10.0 | 26 Jan 2026 | 28 Jun 2026 |
| GenScript PeptidesCASE #VI-2026-0860 | A | 4 | 9.9 | 9.9 | 10.0 | 20 Jun 2026 | 17 Aug 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 3 | 9.9 | 9.9 | 10.0 | 1 Feb 2026 | 1 Jul 2026 |
| Sigma-AldrichCASE #VI-2026-0829 | A | 3 | 9.9 | 9.9 | 10.0 | 14 Jun 2026 | 7 Aug 2026 |
| SinoPepCASE #VI-2026-0387 | A | 3 | 9.9 | 9.9 | 10.0 | 18 Feb 2026 | 14 Aug 2026 |
| AmbioPharmCASE #VI-2026-0177 | A | 3 | 9.9 | 9.9 | 10.0 | 21 Feb 2026 | 14 Jul 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 2 | 9.9 | 9.9 | 10.0 | 5 Feb 2026 | 9 Feb 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 2 | 9.9 | 9.9 | 10.0 | 19 Feb 2026 | 23 Mar 2026 |
| Thermo Fisher ScientificCASE #VI-2026-0142 | A | 2 | 9.9 | 9.9 | 10.0 | 22 Dec 2025 | 20 Mar 2026 |
| Eternal PeptidesCASE #VI-2026-0842 | X | 2 | 9.8 | 9.7 | 10.0 | 3 Jun 2025 | 21 May 2026 |
| PeptiAtlasCASE #VI-2026-0739 | X | 1 | 9.3 | 9.3 | 9.3 | 17 Dec 2024 | 17 Dec 2024 |
| Laicuinuo LCNCASE #VI-2026-0223 | X | 1 | 9.0 | 9.0 | 9.0 | 2 Apr 2025 | 2 Apr 2025 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 3 | 8.9 | 7.6 | 10.0 | 23 May 2026 | 23 May 2026 |
| Peptide TechnologiesCASE #VI-2026-0694 | X | 1 | 8.6 | 8.6 | 8.6 | 25 Apr 2025 | 25 Apr 2025 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 7 | 8.5 | 6.4 | 9.5 | 23 May 2026 | 23 May 2026 |
| Peptide PartnersCASE #VI-2026-0295 | X | 1 | 8.5 | 8.5 | 8.5 | 2 Jul 2025 | 2 Jul 2025 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 8 | 8.3 | 7.5 | 9.3 | 24 May 2026 | 24 May 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 5 | 8.3 | 6.0 | 10.0 | 24 May 2026 | 24 May 2026 |
| Bulk Peptide WholesaleCASE #VI-2026-0319 | A | 2 | 8.3 | 8.3 | 8.3 | 7 May 2025 | 21 May 2026 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 2 | 7.8 | 7.3 | 8.2 | 23 May 2026 | 23 May 2026 |
| Eros PeptidesCASE #VI-2026-0918 | X | 1 | 7.7 | 7.7 | 7.7 | 7 May 2025 | 7 May 2025 |
| Reta-PeptideCASE #VI-2026-0756 | X | 12 | 7.6 | 4.8 | 10.0 | 6 May 2025 | 24 May 2026 |
| Bio PepzCASE #VI-2026-0436 | X | 1 | 7.5 | 7.5 | 7.5 | 25 Apr 2025 | 25 Apr 2025 |
| Lux Synth AminosCASE #VI-2026-0700 | X | 1 | 7.4 | 7.4 | 7.4 | 16 Mar 2025 | 16 Mar 2025 |
| NUPEPS PeptidesCASE #VI-2026-0896 | X | 1 | 7.4 | 7.4 | 7.4 | 9 Jun 2025 | 9 Jun 2025 |
| Mai PeptideCASE #VI-2026-0769 | X | 2 | 7.3 | 6.6 | 8.1 | 28 Mar 2025 | 21 May 2026 |
| HazelCASE #VI-2026-0392 | X | 1 | 7.3 | 7.3 | 7.3 | 28 Mar 2025 | 28 Mar 2025 |
| PeptidologyCASE #VI-2026-0520 | X | 1 | 7.2 | 7.2 | 7.2 | 2 Apr 2025 | 2 Apr 2025 |
| Paradigm PeptideCASE #VI-2026-0759 | X | 1 | 7.2 | 7.2 | 7.2 | 7 May 2025 | 7 May 2025 |
| Huaian Hanyou PeptideCASE #VI-2026-0297 | X | 1 | 7.2 | 7.2 | 7.2 | 7 May 2025 | 7 May 2025 |
| Haikou Mingheng BiotechnologyCASE #VI-2026-0126 | X | 1 | 7.0 | 7.0 | 7.0 | 3 Jun 2025 | 3 Jun 2025 |
| ZLZ PeptideCASE #VI-2026-0524 | X | 5 | 6.9 | 6.1 | 8.5 | 28 Mar 2025 | 20 May 2026 |
| Hebei Rimao TechnologyCASE #VI-2026-0529 | X | 1 | 6.9 | 6.9 | 6.9 | 13 Feb 2025 | 13 Feb 2025 |
| UtherCASE #VI-2026-0902 | X | 4 | 6.8 | 5.5 | 7.8 | 25 Apr 2025 | 24 May 2026 |
| Shanghai OuDaXin New Material Technology CenterCASE #VI-2026-0498 | E | 3 | 6.4 | 5.5 | 7.4 | 7 May 2025 | 19 Jan 2026 |
| HkRoidsCASE #VI-2026-0784 | X | 1 | 6.0 | 6.0 | 6.0 | 2 Jul 2025 | 2 Jul 2025 |
| LSPLCASE #VI-2026-0523 | X | 2 | 5.5 | 5.5 | 5.6 | 28 Mar 2025 | 21 May 2026 |
| TydesCASE #VI-2026-0493 | X | 4 | 5.4 | 3.6 | 7.5 | 3 Jul 2025 | 24 May 2026 |
| Yabang PeptideCASE #VI-2026-0148 | X | 1 | 5.4 | 5.4 | 5.4 | 9 Jun 2025 | 9 Jun 2025 |
| ScienceCASE #VI-2026-0636 | X | 1 | 5.2 | 5.2 | 5.2 | 8 Jul 2025 | 8 Jul 2025 |
| Coastal PeptidesCASE #VI-2026-0958 | X | 1 | 5.2 | 5.2 | 5.2 | 8 Jul 2025 | 8 Jul 2025 |
| Dragon PharmaCASE #VI-2026-0519 | X | 1 | 4.8 | 4.8 | 4.8 | 2 Apr 2025 | 2 Apr 2025 |
| Golden EagleCASE #VI-2026-0680 | X | 1 | 4.7 | 4.7 | 4.7 | 20 Jun 2025 | 20 Jun 2025 |
| Xingtai Pukelai Technology CoCASE #VI-2026-0850 | X | 1 | 4.6 | 4.6 | 4.6 | 14 Jan 2025 | 14 Jan 2025 |
| Coffee and PeppersCASE #VI-2026-0274 | X | 1 | 3.5 | 3.5 | 3.5 | 28 Mar 2025 | 28 Mar 2025 |
| Advanced Technology and IndustrialCASE #VI-2026-0133 | X | 1 | 1.5 | 1.5 | 1.5 | 2 Apr 2025 | 2 Apr 2025 |
| PepKitsCASE #VI-2026-0320 | X | 1 | 0.3 | 0.3 | 0.3 | 17 Dec 2024 | 17 Dec 2024 |
| HK Fat CatCASE #VI-2026-0376 | X | 1 | 0.0 | 0.0 | 0.0 | 9 Jun 2025 | 9 Jun 2025 |
| PepLab SolutionsCASE #VI-2026-0431 | X | 1 | 0.0 | 0.0 | 0.0 | 20 Jun 2025 | 20 Jun 2025 |
Open any subject to view the batch-level evidence for LGD-4033 (Ligandrol) alone.